---
layout: default
title: Lactic Acid
parent: 僅模型預測 (L5)
nav_order: 437
evidence_level: L5
indication_count: 10
---

# Lactic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lactic Acid: From No Approved Indication to Atypical Coarctation of Aorta

## One-Sentence Summary

Lactic acid (DrugBank ID DB04398) currently has no approved indication on record and is not marketed. The TxGNN model's top-ranked prediction suggests a possible link to **atypical coarctation of aorta**, but this prediction is currently supported by **zero clinical trials** and **zero publications**, and no biological mechanism connecting lactic acid to this congenital aortic malformation is known.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | No approved indication on record |
| Predicted New Indication | Atypical Coarctation of Aorta |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| Canada Market Status | Not marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for lactic acid is not available in this evidence pack. Lactic acid is an endogenous metabolite of glycolysis and is more commonly encountered pharmaceutically as an excipient or pH-adjusting agent (e.g., in intravenous fluids, topical/vaginal formulations) rather than as an active therapeutic agent with a defined indication — consistent with the absence of any registered license or approved indication in this dataset.

For this specific candidate, the model's own rationale is explicit that no mechanistic hypothesis exists: "無機轉假說；乳酸與主動脈結構性畸形間無已知生物學關聯，純屬 TxGNN 圖譜相似性預測" (No mechanistic hypothesis; there is no known biological relationship between lactic acid and structural aortic malformation — this is purely a TxGNN knowledge-graph similarity prediction). Atypical coarctation of aorta is a structural, largely congenital or post-inflammatory anatomic anomaly of the aorta, and there is no established pathway by which a small-molecule metabolic intermediate would correct or prevent such a structural defect.

Given the complete absence of clinical trials, literature, and a plausible mechanism, this prediction should be treated as a graph-similarity artifact rather than a genuine repurposing signal at this time.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Canada Market Information

Lactic acid has 0 registered licenses on file and is currently **not marketed**. No authorized product records are available for review.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (atypical coarctation of aorta) has no supporting clinical trials, no literature, and no known mechanistic rationale — it scores at Evidence Level L5 (model prediction only) and is explicitly flagged by the model's own rationale as a graph-similarity artifact rather than a biologically plausible repurposing lead.

**To proceed, the following is needed:**
- Mechanism of action (MOA) data for lactic acid (currently a blocking data gap)
- TFDA/regulatory label data on warnings and contraindications (currently a blocking data gap for safety review)
- Independent mechanistic or preclinical rationale connecting lactic acid to any cardiovascular structural indication before further investment
- Consider redirecting evaluation resources toward higher-evidence candidates in this same evidence pack — notably rank 5 ("dry eye syndrome"), which reached decision stage S1 with 6 trials and 9 publications, though its literature also raises a pathogenic (pro-inflammatory) rather than therapeutic signal that would need to be resolved before advancing
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

